Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment

Head and Neck

Volumn 35, Issue 2, 2013, Pages 294-306

  Lucs, Alexandra V ^a   Saltman, Benjamin ^b   Chung, Christine H ^c   Steinberg, Bettie M ^a,b   Schwartz, David L ^a,b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; DNA damage repair; epidermal growth factor receptor; functional imaging; head and neck cancer; human papillomavirus; magnetic resonance imaging; microarray; noncoding RNA; personalized therapy; positron emission tomography; prognosis; radiotherapy; treatment response

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; GROWTH FACTOR RECEPTOR; MESSENGER RNA;

CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RESEARCH; CANCER THERAPY; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; DNA DAMAGE; DNA REPAIR; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE IN SITU HYBRIDIZATION; HEAD AND NECK CANCER; HIGH THROUGHPUT SCREENING; HUMAN; HYPOXIA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPILLOMAVIRUS INFECTION; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; VIRAL TROPISM;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; MALE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84872766598     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21975     Document Type: Review

References (211)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. de Bree R, Leemans CR,. Recent advances in surgery for head and neck cancer. Curr Opin Oncol 2010; 22: 186-193.
3. Dirix P, Nuyts S,. Evidence-based organ-sparing radiotherapy in head and neck cancer. Lancet Oncol 2010; 11: 85-91.
4. Lorch JH, Posner MR, Wirth LJ, Haddad RI,. Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am 2008; 22: 1155-1163, viii.
5. Argiris A, Karamouzis MV, Raben D, Ferris RL,. Head and neck cancer. Lancet 2008; 371: 1695-1709.
6. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
7. Razak AR, Siu LL, Le Tourneau C,. Molecular targeted therapies in all histologies of head and neck cancers: an update. Curr Opin Oncol 2010; 22: 212-220.
8. Corry J, Peters LJ, Rischin D,. Optimising the therapeutic ratio in head and neck cancer. Lancet Oncol 2010; 11: 287-291.
9. Groome PA, Schulze K, Boysen M, Hall SF, Mackillop WJ,. A comparison of published head and neck stage groupings in carcinomas of the oral cavity. Head Neck 2001; 23: 613-624.
10. Groome PA, Schulze KM, Mackillop WJ, et al. A comparison of published head and neck stage groupings in carcinomas of the tonsillar region. Cancer 2001; 92: 1484-1494.
11. Groome PA, Schulze K, Boysen M, et al. A comparison of published head and neck stage groupings in laryngeal cancer using data from two countries. J Clin Epidemiol 2002; 55: 533-544.
12. Dancey JE, Dobbin KK, Groshen S, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010; 16: 1745-1755.
13. Reed AB, Parekh DJ,. Biomarkers for prostate cancer detection. Expert Rev Anticancer Ther 2010; 10: 103-114.
14. Jordan VC, Osipo C, Schafer JM, Fox JE, Cheng D, Liu H,. Changing role of the oestrogen receptor in the life and death of breast cancer cells. Breast 2003; 12: 432-441.
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
16. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
17. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
18. Sawyers CL,. The cancer biomarker problem. Nature 2008; 452: 548-552.
19. Doorbar J,. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110: 525-541.
20. Chow LT, Broker TR, Steinberg BM,. The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 2010; 118: 422-449.
21. Pyeon D, Newton MA, Lambert PF, et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007; 67: 4605-4619.
22. Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I,. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol 2011; 29: 739-746.
23. Shiboski CH, Schmidt BL, Jordan RC,. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 2005; 103: 1843-1849.
24. Sturgis EM, Cinciripini PM,. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 2007; 110: 1429-1435.
25. Hammarstedt L, Lindquist D, Dahlstrand H, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006; 119: 2620-2623.
26. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956.
27. Smith EM, Ritchie JM, Summersgill KF, et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004; 108: 766-772.
28. Smith EM, Ritchie JM, Summersgill KF, et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004; 96: 449-455.
29. Kreimer AR, Clifford GM, Boyle P, Franceschi S,. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-475.
30. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630-5636.
31. Fakhry Z, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous carcinoma in a prospective trial. J Natl Cancer Inst 2008; 100: 261-269.
32. Kumar B, Cordell KG, Lee JS, et al. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys 2007; 69 (Suppl 2): S109-S111.
33. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
34. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J,. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992-1998.
35. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-4148.
36. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009; 27: 6213-6221.
37. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-747.
38. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 2010; 16: 1226-1235.
39. Huang SM, Bock JM, Harari PM,. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-1940.
40. Milas L, Fan Z, Andratschke NH, Ang KK,. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 2004; 58: 966-971.
41. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-832.
42. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-7356.
43. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
44. Ludes-Meyers JH, Subler MA, Shivakumar CV, et al. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 1996; 16: 6009-6019.
45. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24: 4170-4176.
46. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25: 2164-2170.
47. Lee JW, Soung YH, Kim SY, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 2879-2882.
48. Cohen EE, Lingen MW, Martin LE, et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005; 11: 8105-8108.
49. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12: 5064-5073.
50. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA,. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-8654.
51. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-5577.
52. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
53. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
54. Karamouzis MV, Grandis JR, Argiris A,. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. J Am Med Assoc 2007; 298: 70-82.
55. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005; 23: 5560-5567.
56. Freier K, Joos S, Flechtenmacher C, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 2003; 63: 1179-1182.
57. Pectasides E, Rampias T, Kountourakis P, et al. Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma. Clin Cancer Res 2011; 17: 2947-2954.
58. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R,. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007; 13: 4291-4299.
59. Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest 1998; 102: 1385-1392.
60. Zhang Q, Thomas SM, Xi S, et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004; 64: 6166-6173.
61. Xi S, Zhang Q, Dyer KF, et al. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 2003; 278: 31574-31583.
62. Pectasides E, Egloff AM, Sasaki C, et al. Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res 2010; 16: 2427-2434.
63. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128-3137.
64. Kong CS, Narasimhan B, Cao H, et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009; 74: 553-561.
65. Young RJ, Rischin D, Fisher R, et al. Relationship between epidermal growth factor receptor status, p16INK4A, and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2011; 20: 1230-1237.
66. Dittmann K, Mayer C, Rodemann HP,. Inhibition of radiation-induced EGFR nuclear import by C225 (cetuximab) suppresses DNA-PK activity. Radiother Oncol 2005; 76: 157-161.
67. Psyrri A, Yu Z, Weinberger PM, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005; 11: 5856-5862.
68. Psyrri A, Egleston B, Weinberger P, et al. Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray. Cancer Epidemiol Biomarkers Prev 2008; 17: 1486-1492.
69. Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004; 5: 489-500.
70. Chung CH, Parker JS, Ely K, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 2006; 66: 8210-8218.
71. Slebos RJ, Yi Y, Ely K, et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 701-709.
72. Winter SC, Buffa FM, Silva P, et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007; 67: 3441-3449.
73. Roepman P, Wessels LF, Kettelarij N, et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 2005; 37: 182-186.
74. Liu CJ, Liu TY, Kuo LT, et al. Differential gene expression signature between primary and metastatic head and neck squamous cell carcinoma. J Pathol 2008; 214: 489-497.
75. Reis EM, Ojopi EP, Alberto FL, et al. Large-scale transcriptome analyses reveal new genetic marker candidates of head, neck, and thyroid cancer. Cancer Res 2005; 65: 1693-1699.
76. Roepman P, Kemmeren P, Wessels LF, Slootweg PJ, Holstege FC,. Multiple robust signatures for detecting lymph node metastasis in head and neck cancer. Cancer Res 2006; 66: 2361-2366.
77. Li Y, Elashoff D, Oh M, et al. Serum circulating human mRNA profiling and its utility for oral cancer detection. J Clin Oncol 2006; 24: 1754-1760.
78. Chin D, Boyle GM, Williams RM, et al. Novel markers for poor prognosis in head and neck cancer. Int J Cancer 2005; 113: 789-797.
79. Rentoft M, Laurell G, Coates PJ, Sjostrom B, Nylander K,. Gene expression profiling of archival tongue squamous cell carcinomas provides sub-classification based on DNA repair genes. Int J Oncol 2009; 35: 1321-1330.
80. Thurlow JK, Pena Murillo CL, Hunter KD, et al. Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. J Clin Oncol 2010; 28: 2881-2888.
81. Ziober AF, Patel KR, Alawi F, et al. Identification of a gene signature for rapid screening of oral squamous cell carcinoma. Clin Cancer Res 2006; 12: 5960-5971.
82. Li Y, St John MA, Zhou X, et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 2004; 10: 8442-8450.
83. Roesch-Ely M, Leipold A, Nees M, et al. Proteomic analysis of field cancerization in pharynx and oesophagus: a prospective pilot study. J Pathol 2010; 221: 462-470.
84. Roesch-Ely M, Nees M, Karsai S, et al. Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 2007; 26: 54-64.
85. Patel V, Hood BL, Molinolo AA, et al. Proteomic analysis of laser-captured paraffin-embedded tissues: a molecular portrait of head and neck cancer progression. Clin Cancer Res 2008; 14: 1002-1014.
86. Lallemant B, Evrard A, Combescure C, et al. Clinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse. BMC Cancer 2009; 9: 370 (abstract).
87. Callesen AK, Madsen JS, Vach W, Kruse TA, Mogensen O, Jensen ON,. Serum protein profiling by solid phase extraction and mass spectrometry: a future diagnostics tool? Proteomics 2009; 9: 1428-1441.
88. Fabian TK, Fejerdy P, Csermely P,. Salivary genomics, transcriptomics and proteomics: the emerging concept of the oral ecosystem and their use in the early diagnosis of cancer and other diseases. Curr Genomics 2008; 9: 11-21.
89. Hardt M, Witkowska HE, Webb S, et al. Assessing the effects of diurnal variation on the composition of human parotid saliva: quantitative analysis of native peptides using iTRAQ reagents. Anal Chem 2005; 77: 4947-4954.
90. Hu S, Arellano M, Boontheung P, et al. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 2008; 14: 6246-6252.
91. de Jong EP, Xie H, Onsongo G, et al. Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions. PLoS One 2010; 5: 11148.
92. Righini CA, de Fraipont F, Timsit JF, et al. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res 2007; 13: 1179-1185.
93. Tachezy R, Klozar J, Rubenstein L, et al. Demographic and risk factors in patients with head and neck tumors. J Med Virol 2009; 81: 878-887.
94. Chuang AY, Chuang TC, Chang S, et al. Presence of HPV DNA in convalescent salivary rinses is an adverse prognostic marker in head and neck squamous cell carcinoma. Oral Oncol 2008; 44: 915-919.
95. Dowling P, Wormald R, Meleady P, Henry M, Curran A, Clynes M,. Analysis of the saliva proteome from patients with head and neck squamous cell carcinoma reveals differences in abundance levels of proteins associated with tumour progression and metastasis. J Proteomics 2008; 71: 168-175.
96. Helmerhorst EJ, Oppenheim FG,. Saliva: a dynamic proteome. J Dent Res 2007; 86: 680-693.
97. Meyer F, Samson E, Douville P, Duchesne T, Liu G, Bairati I,. Serum prognostic markers in head and neck cancer. Clin Cancer Res 2010; 16: 1008-1015.
98. Freed GL, Cazares LH, Fichandler CE, et al. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. Laryngoscope 2008; 118: 61-68.
99. Gourin CG, Zhi W, Adam BL,. Proteomic identification of serum biomarkers for head and neck cancer surveillance. Laryngoscope 2009; 119: 1291-1302.
100. Soltys SG, Le QT, Shi G, Tibshirani R, Giaccia AJ, Koong AC,. The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers. Clin Cancer Res 2004; 10: 4806-4812.
101. Fan Y, Shi L, Liu Q, et al. Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol Cancer 2009; 8:Art. 79.
102. Chung CH, Seeley EH, Roder H, et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev 2010; 19: 358-365.
103. Byers LA, Holsinger FC, Kies MS, et al. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 2010; 9: 1755-1763.
104. Kim MK, Cho KJ, Kwon GY, et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 2008; 14: 4225-4231.
105. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
106. Handra-Luca A, Hernandez J, Mountzios G, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13: 3855-3859.
107. Jun HJ, Ahn MJ, Kim HS, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 2008; 99: 167-172.
108. Sherr CJ, McCormick F,. The RB and p53 pathways in cancer. Cancer Cell 2002; 2: 103-112.
109. Gudkov AV, Komarova EA,. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003; 3: 117-129.
110. Soussi T, Kato S, Levy PP, Ishioka C,. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005; 25: 6-17.
111. Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H,. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003; 63: 1188-1191.
112. Opitz OG, Suliman Y, Hahn WC, Harada H, Blum HE, Rustgi AK,. Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J Clin Invest 2001; 108: 725-732.
113. Rheinwald JG, Hahn WC, Ramsey MR, et al. A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 2002; 22: 5157-5172.
114. Bode AM, Dong Z,. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4: 793-805.
115. Sharpless NE, DePinho RA,. p53: good cop/bad cop. Cell 2002; 110: 9-12.
116. Quon H, Liu FF, Cummings BJ,. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001; 23: 147-159.
117. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357: 2552-2261.
118. Harden SV, Thomas DC, Benoit N, et al. Real-time gap ligase chain reaction: a rapid semiquantitative assay for detecting p53 mutation at low levels in surgical margins and lymph nodes from resected lung and head and neck tumors. Clin Cancer Res 2004; 10: 2379-2385.
119. Hall E, Giaccia A,. Radiobiology for the radiologist. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
120. Moeller BJ, Yordy JS, Williams MD, et al. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res 2011; 17: 2035-2043.
121. Mahaney BL, Meek K, Lees-Miller SP,. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J 2009; 417: 639-650.
122. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-943.
123. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P,. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-4515.
124. Nordsmark M, Overgaard J,. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000; 57: 39-43.
125. Semenza GL,. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88: 1474-1480.
126. Semenza GL,. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
127. Schwartz DL, Bankson JA, Lemos R Jr, et al. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 2010; 9: 2057-2067.
128. Schwartz DL, Powis G, Thitai-Kumar A, et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 2009; 8: 947-958.
129. Hui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002; 8: 2595-2604.
130. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 53: 1192-1202.
131. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911-2916.
132. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006; 24: 727-735.
133. Brockton N, Dort J, Lau H, et al. High stromal carbonic anhydrase IX expression is associated with decreased survival in P16-negative head-and-neck tumors. Int J Radiat Oncol Biol Phys 2011; 80: 249-257.
134. Le QT, Harris J, Magliocco AM, et al. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol 2009; 27: 4281-4286.
135. Le QT, Shi G, Cao H, et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005; 23: 8932-8941.
136. Le QT, Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003; 9: 59-67.
137. Mandal M, Myers JN, Lippman SM, et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 2008; 112: 2088-2100.
138. Chung CH, Dignam JJ, Hammond ME, et al. Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol 2011; 29: 1326-1334.
139. Ito E, Yue S, Moriyama EH, et al. Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Sci Transl Med 2011; 3: 67ra7.
140. Bodily JM, Mehta KP, Laimins LA,. Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Cancer Res 2011; 71: 1187-1195.
141. Bartel DP,. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
142. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
143. Dalmay T,. MicroRNAs and cancer. J Intern Med 2008; 263: 366-375.
144. Mattie MD, Benz CC, Bowers J, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006; 5:Art. 24.
145. Tricoli JV, Jacobson JW,. MicroRNA: potential for cancer detection, diagnosis, and prognosis. Cancer Res 2007; 67: 4553-4555.
146. Blenkiron C, Goldstein LD, Thorne NP, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007; 8:Art. R214.
147. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI,. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008; 14: 2588-2592.
148. Avissar M, Christensen BC, Kelsey KT, Marsit CJ,. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 2009; 15: 2850-2855.
149. Chang KW, Liu CJ, Chu TH, et al. Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma. J Dent Res 2008; 87: 1063-1068.
150. Ramdas L, Giri U, Ashorn CL, et al. miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck 2009; 31: 642-654.
151. Chang SS, Jiang WW, Smith I, et al. MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer 2008; 123: 2791-2797.
152. Li J, Huang H, Sun L, et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 2009; 15: 3998-4008.
153. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ,. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007; 6:Art. 5.
154. Liu CJ, Tsai MM, Hung PS, et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res 2010; 70: 1635-1644.
155. Hui AB, Lenarduzzi M, Krushel T, et al. Comprehensive microRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 2010; 16: 1129-1139.
156. Lu J, He ML, Wang L, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011; 71: 225-233.
157. Simon R, Maitournam A,. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004; 10: 6759-6763.
158. 18F- fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008; 100: 712-720.
159. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004; 22: 4357-4368.
160. Czernin J, Allen-Auerbach M, Schelbert HR,. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007; 48 (Suppl 1): 78S-88S.
161. Facey K, Bradbury I, Laking G, Payne E,. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 2007; 11: iii-iv, xi-267.
162. Syed R, Bomanji JB, Nagabhushan N, et al. Impact of combined (18)F-FDG PET/CT in head and neck tumours. Br J Cancer 2005; 92: 1046-1050.
163. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM,. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004; 231: 65-72.
164. Schwartz DL, Ford E, Rajendran J, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 61: 129-136.
165. Veit-Haibach P, Luczak C, Wanke I, et al. TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging 2007; 34: 1953-1962.
166. Gregoire V,. Is there any future in radiotherapy planning without the use of PET: unraveling the myth. Radiother Oncol 2004; 73: 261-263.
167. 18F]fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol 2009; 27: 2509-2515.
168. Moeller BJ, Rana V, Cannon BA, et al. Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. Int J Radiat Oncol Biol Phys 2010; 78: 667-674.
169. Ryan WR, Fee WE Jr, Le QT, Pinto HA,. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005; 115: 645-650.
170. Yao M, Graham MM, Smith RB, et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int J Radiat Oncol Biol Phys 2004; 60: 1410-1418.
171. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 2005; 27: 175-181.
172. 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008; 49: 532-540.
173. Yao M, Hoffman HT, Chang K, et al. Is planned neck dissection necessary for head and neck cancer after intensity-modulated radiotherapy? Int J Radiat Oncol Biol Phys 2007; 68: 707-713.
174. Liauw SL, Mancuso AA, Amdur RJ, et al. Postradiotherapy neck dissection for lymph node-positive head and neck cancer: the use of computed tomography to manage the neck. J Clin Oncol 2006; 24: 1421-1427.
175. Tan A, Adelstein DJ, Rybicki LA, et al. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2007; 133: 435-440.
176. Gourin CG, Williams HT, Seabolt WN, Herdman AV, Howington JW, Terris DJ,. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngoscope 2006; 116: 705-710.
177. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2005; 63: 991-999.
178. Greven KM, Williams DW III, McGuirt WF Sr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001; 23: 942-946.
179. 18F]FDG PET in clinical oncology. Lancet Oncol 2007; 8: 822-830.
180. Vallabhajosula S,. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 2007; 37: 400-419.
181. 18F]fluorothymidine. Semin Nucl Med 2007; 37: 429-439.
182. 18F-fluoromisonidazole. Semin Nucl Med 2007; 37: 451-461.
183. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006; 12: 5435-5441.
184. 18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; 75: 101-108.
185. Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA,. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging 2006; 33 (Suppl 1): 44-53.
186. Thorwarth D, Eschmann SM, Paulsen F, Alber M,. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys 2007; 68: 291-300.
187. 18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004; 31: 1464-1470.
188. 18F] fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005; 32: 422-429.
189. Inoue T, Tomiyoshi K, Higuichi T, et al. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent. J Nucl Med 1998; 39: 663-667.
190. 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006; 47: 904-911.
191. 11C-acetate. J Nucl Med 2007; 48: 420-428.
192. Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN,. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med 2007; 37: 420-428.
193. Solberg TD, Nearman J, Mullins J, Li S, Baranowska-Kortylewicz J,. Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72: 918-926.
194. Sherman SI,. Molecularly targeted therapies for thyroid cancers. Endocr Pract 2009; 15: 605-611.
195. Hylton N,. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006; 24: 3293-3298.
196. Jackson A, O'Connor JP, Parker GJ, Jayson GC,. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007; 13: 3449-3459.
197. Ceelen W, Smeets P, Backes W, et al. Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. Int J Radiat Oncol Biol Phys 2006; 64: 1188-1196.
198. Kobayashi H, Reijnders K, English S, et al. Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin Cancer Res 2004; 10: 7712-7720.
199. Crokart N, Jordan BF, Baudelet C, et al. Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int J Radiat Oncol Biol Phys 2005; 63: 901-910.
200. Baba Y, Furusawa M, Murakami R, et al. Role of dynamic MRI in the evaluation of head and neck cancers treated with radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 783-787.
201. Hoskin PJ, Saunders MI, Goodchild K, Powell ME, Taylor NJ, Baddeley H,. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol 1999; 72: 1093-1098.
202. Tomura N, Omachi K, Sakuma I, et al. Dynamic contrast-enhanced magnetic resonance imaging in radiotherapeutic efficacy in the head and neck tumors. Am J Otolaryngol 2005; 26: 163-167.
203. Semiz Oysu A, Ayanoglu E, Kodalli N, Oysu C, Uneri C, Erzen C,. Dynamic contrast-enhanced MRI in the differentiation of posttreatment fibrosis from recurrent carcinoma of the head and neck. Clin Imaging 2005; 29: 307-312.
204. Kim S, Quon H, Loevner LA, et al. Transcytolemmal water exchange in pharmacokinetic analysis of dynamic contrast-enhanced MRI data in squamous cell carcinoma of the head and neck. J Magn Reson Imaging 2007; 26: 1607-1617.
205. Cao Y, Popovtzer A, Li D, et al. Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. Int J Radiat Oncol Biol Phys 2008; 72: 1287-1290.
206. Wang H, Dong L, Mohan R, et al. Implementation and validation of a deformable image registration algorithm for in-room CT-guided radiotherapy. Med Phys 2004; 31: 1791 (abstract).
207. Chenevert TL, McKeever PE, Ross BD,. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 1997; 3: 1457-1466.
208. Vandecaveye V, De Keyzer F, Nuyts S, et al. Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys 2007; 67: 960-971.
209. Kim S, Loevner L, Quon H, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009; 15: 986-994.
210. Goodsaid FM, Mendrick DL,. Translational medicine and the value of biomarker qualification. Sci Transl Med 2010; 2: 47-44.
211. Buckler AJ, Bresolin L, Dunnick NR, Sullivan DC,. A collaborative enterprise for multi-stakeholder participation in the advancement of quantitative imaging. Radiology 2011; 258: 906-914.